Intron retention may regulate expression of Epstein-Barr virus nuclear antigen 3 family genes by Kienzle, Norbert et al.
JOURNAL OF VIROLOGY,
0022-538X/99/$04.0010
Feb. 1999, p. 1195–1204 Vol. 73, No. 2
Copyright © 1999, American Society for Microbiology. All Rights Reserved.
Intron Retention May Regulate Expression of Epstein-Barr
Virus Nuclear Antigen 3 Family Genes
NORBERT KIENZLE,* DAVID B. YOUNG,† DAPHNE LIASKOU, MARION BUCK,
SONIA GRECO, AND TOM B. SCULLEY
EBV Unit, The Queensland Institute of Medical Research and University of
Queensland Joint Oncology Program, Brisbane, Australia
Received 4 September 1998/Accepted 26 October 1998
The nuclear antigen 3 family genes (EBNA-3, EBNA-4, and EBNA-6) of Epstein-Barr virus (EBV) are im-
portant for EBV-induced immortalization and survival of B lymphocytes. However, little is known about how
the expression of these genes is regulated. Each of the EBNA-3, EBNA-4, and EBNA-6 genes consists of two
exons separated by a small intron. Reverse transcriptase PCR assays revealed that the vast majority of the
EBNA-3, EBNA-4, and EBNA-6 mRNA, expressed in transfected and EBV-infected B cells, retained intron
sequences. Northern blot and S1 protection assays confirmed that most of the EBNA-3 mRNA contained
intron. Examination of deletion mutants of EBNA-3 indicated that the EBNA-3 protein was not necessary for
intron retention and that there was no splicing silencing element encoded in the EBNA-3 mRNA. Cell frac-
tionation and RNA gradient analysis revealed that the unspliced EBNA 3 family mRNAs were transported into
the cytoplasm and associated with the polysomes. However, Western blot analysis of FLAG-epitope tagged
EBNA-3 gave no indication of the presence of splice variant protein forms of EBNA-3. In contrast, transiently
transfected cells expressing EBNA-3 revealed a sixfold increase in EBNA-3 protein expression from the geno-
mic EBNA-3 gene compared to EBNA-3 cDNA. These data show that the intronic sequences can influence
EBNA-3 protein expression and suggest that intron retention may provide a means for the fine-tuning of ex-
pression of the individual EBNA 3 family genes.
Epstein-Barr virus (EBV) is a human gammaherpesvirus
which infects at least 90% of the world’s population. EBV is
the etiological agent of infectious mononucleosis and is asso-
ciated with a variety of lymphoid and epithelial cancers includ-
ing Burkitt’s lymphoma (BL), nasopharyngeal carcinoma, and
Hodgkin’s disease. The oncogenic potential of EBV is reflect-
ed in its ability to efficiently transform and immortalize human
B cells in vitro. The resulting latently infected lymphoblastoid
cell lines (LCLs) express a restricted set of EBV genes encod-
ing six nuclear antigens (EBNA-1 through EBNA-6) and three
latent membrane proteins (LMP-1, TP-1, and TP-2). At least
two different EBV types exist, A and B (also called I and II),
which are classified by sequence divergence in the genes en-
coding EBNA-2, EBNA-3, EBNA-4, and EBNA-6 (reviewed
in reference 18). The pattern of latent EBV gene expression,
present in LCLs, is also found during primary B-lymphocyte
infection in vivo and in EBV-associated lymphoproliferative
disease (39), emphasizing that regulation of latent gene expres-
sion is likely to be important in the process of EBV-mediated
B-cell transformation, virus persistence, and lymphomagen-
esis.
The persistent expression of the EBNA 3 gene family prod-
ucts, EBNA-3, EBNA-4, and EBNA-6 (also known as EBNA-
3a, EBNA-3b, and EBNA-3c) against negative selective
pressure by cytotoxic T cells in vivo (28) is consistent with an
important role for these genes. Indeed, it was shown that
EBNA-3 and EBNA-6 were essential for B-cell immortaliza-
tion (40) and that EBNA-4 enhanced the survival of cells prone
to undergo apoptosis (35). Expression of the individual genes
of the EBNA 3 family resulted in transactivation or repression
of viral and cellular genes, suggesting a role as transcriptional
regulators (1, 19, 22, 24, 43). Indeed, we and others have shown
that EBNA-3, EBNA-4, and EBNA-6 form stable complexes
with the cellular DNA-binding factor RBP-Jk/2N, leading to
inhibition of EBNA-2-mediated modulation of gene expres-
sion (21, 24, 30, 45). Therefore, the EBNA 3 gene family may
function by differentially regulating viral and cellular genes
whose promoters contain RBP-Jk/2N-binding sites (31, 42),
illustrating the importance of maintaining adequate control
over the expression levels of EBNA-3, EBNA-4, and EBNA-6.
The three genes of the EBNA 3 family have a similar geno-
mic organization, consisting of two exons separated by a small
intron (Fig. 1). These genes encode nuclear proteins of 944,
938, and 992 amino acids (aa), respectively, and have structural
and sequence homologies (22, 33). The two types of EBV are
divergent, at the nucleotide level, within the coding regions of
the EBNA 3 family of genes (33). In contrast, the intronic
regions of these genes are remarkably homologous (95 to 98%)
between A- and B-type viruses, indicating a selective conser-
vation despite the evolutionary emergence of two distinctive
EBV types. In LCLs, the EBNA genes are transcribed into a
'110-kb primary multicistronic transcript which originates
from either the Cp or Wp promoters (44). The Cp promoter
itself can be activated by the EBNA-2 protein via RBP-Jk/2N,
thereby providing a mechanism for control of viral gene ex-
pression at the transcriptional level (32). However, only limited
data is available on the metamorphosis of the primary tran-
script into the fully processed EBNA-3, EBNA-4, and EBNA-6
mRNAs. Proposed posttranscriptional mechanisms include al-
ternative splicing and polyadenylation site selection, resulting
in a very low abundance of mRNAs containing the EBNA 3
family genes (38).
There is no evidence that expression of the EBNA-3,
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EBNA-4, and EBNA-6 genes can be individually regulated.
However, the strong conservation of the introns of the EBNA
3 gene family prompted us to investigate their potential in
regulating gene expression. Indeed, this study demonstrates
that the vast majority of mRNA containing EBNA-3, EBNA-4,
and EBNA-6 contain intronic sequences and provides evidence
that EBV may use this intron retention to fine-tune the ex-
pression of the EBNA 3 family genes.
MATERIALS AND METHODS
Cell lines. QIMR-ISM (Wil), QIMR-MP (B95.8), QIMR-SB (B95.8), and
QIMR-KT (B95.8) are EBV-positive LCLs established by infection of human B
lymphocytes from donors ISM, MP, SB, and KT with the EBV A-type virus
strains Wil or B95.8. MutuIII-c95 is an EBV-positive group III BL cell line (13).
All of these cell lines expressed the full set of EBV latent antigens as indicated
by immunoblot and cytotoxic T-cell assays. DG75 is an EBV-negative BL cell line
(4). Cells were maintained in RPMI 1640 medium supplemented with 2 mM
glutamine, 60 mg of benzylpenicillin per ml, 100 mg of streptomycin per ml, and
10% fetal calf serum (growth medium) at 37°C in a 5% CO2 atmosphere.
Expression vector constructs. The generation of EE3, EE4, EE6, EE346, and
vector control transfectants has been reported elsewhere (19). Briefly, the epi-
some-based shuttle vector EBO-pLPP (23), which contains the oriP/EBNA-1
replicon of EBV, a simian virus 40 (SV40) transcriptional cassette, and the
hygromycin resistance gene, was used to generate expression vectors containing
the genes of the EBNA 3 family. The EBNA-3, EBNA-4, and EBNA-6 genes
were derived from plasmid pACYC184-H3E, which contained the genomic
HindIIIE fragment of A-type EBV strain M-ABA (27).
To generate expression vectors encoding mutated forms of EBNA-3, the
HindIII-CelII fragment of plasmid pACYC184-H3E (positions 91821 to 95369
according to the B95.8 sequence [3] containing the genomic EBNA-3 gene
sequence) was subcloned into pBluescriptKS (Stratagene) (HindIII-XbaI end
filled). This vector construct was used to modify EBNA-3 or cut it with the
appropriate enzymes shown in Fig. 6A, and the mutated EBNA-3 sequences
were then shuttled back into the expression vector EBO-pLPP by using HindIII
and NotI. A frameshift mutation (EBO-E3M) was introduced into exon 1 of
EBNA-3 by digestion with BglII (position 92538) (3), end filling with T4 DNA
polymerase and religation. To generate a FLAG-tagged EBNA-3, an oligo-
adapter containing a BamHI-BglII-flanked FLAG epitope sequence (DYKD-
DDK) was inserted in frame into the BglII site of exon 1 of EBNA-3. The
expression plasmid EBO-EBNA3(S), which contained the spliced form of
EBNA-3, was created by exchanging the genomic BglII-BglII fragment of
EBNA-3 (which contained the end of exon 1, the intron, and part of exon 2
[positions 92538 to 93424 according to the B95.8 sequence]) with the BglII-BglII
fragment of the cDNA of EBNA-3. The genomic HindIII-CelII fragment con-
taining the EBNA-3 gene was also subcloned into the episomal expression vector
pREP4 (Invitrogen) by using HindIII and NotI, thereby creating plasmid REP-
E3. In this plasmid, EBNA-3 transcription was driven by the Rous sarcoma
virus (RSV) promoter. To generate an EBNA-1-deleted EBNA-3 expression
vector (REP/DE1-E3), pREP4 was cut with SacI and StuI (thereby deleting
the N-terminal 486 aa of the 641-aa EBNA-1 coding region), end filled, and
religated, and EBNA-3 was cloned into its HindIII and NotI polylinker sites.
Cell transfection. Exponentially growing DG75 cells (3 3 106 to 5 3 106) were
washed in growth medium, transfected in growth medium with plasmid DNA (12
mg for stable transfection; up to 25 mg for transient transfection) with the Bio-
Rad Gene Pulser (960 mF, 240 V, 0.4-cm gap electrode, room temperature,
350-ml assay volume), and finally resuspended in 5 ml of growth medium. After
2 days, the cells were either analyzed for transient expression or selected with 600
mg of hygromycin B (Boehringer Mannheim, Castle Hill Australia) per ml. Poly-
clonal transfectants grew out after 2 to 3 weeks and were stably maintained in
hygromycin B-containing growth medium. Parental DG75 cells were stably trans-
fected with the individual EBO-EBNA3, EBO-EBNA4, and EBO-EBNA6 ex-
pression vectors (EE3, EE4, and EE6), with vector EBO-EBNA346 encoding the
complete EBNA 3 gene family (EE346), and with constructs expressing mutated
or truncated forms of EBNA-3 or with the control vector EBO-pLPP alone.
RNA purification. Total cellular RNA and mRNA was prepared from 5 3 106
to 10 3 106 exponentially growing cells by using one of three commercially
available RNA kits which were based on the guanidinium thiocyanate purifica-
tion method (RNAgents Total RNA isolation system, Promega; Total RNA
isolation reagent, Advanced Biotechnologies; QuickPrep Micro mRNA purifi-
cation kit, Pharmacia). Total RNA (40 mg) or mRNA (4 mg) was incubated with
30 U of RNase-free DNase I (Boehringer Mannheim) in the presence of PCR
buffer (10 mM Tris-HCl [pH 8.3], 50 mM KCl, 1.5 mM MgCl2), 40 U of RNase
inhibitor (Boehringer Mannheim), and 5 mM dithiothreitol for 50 min at 37°C in
a total volume of 80 ml. The RNA was finally purified by phenol-chloroform
extraction followed by isopropanol precipitation. The purity of the RNA was
determined by measuring the absorbance at 260 and 280 nm (A260/280), and its
integrity was verified on a formamide-agarose gel. Alternatively, the DNase I
treatment of RNA was performed before the addition of both the reverse
transcriptase (RT) enzyme and oligo(dT) primers in RT buffer. The DNase I was
heat inactivated (5 min at 90°C followed by 5 min at 70°C) and the samples were
directly used for the RT reaction.
RNA fraction and polysome gradient. Fractionation of RNA was performed by
modified protocols (8, 16). Cells (4 3 107) were washed twice in ice-cold phos-
phate-buffered saline (PBS) and were then disrupted with 0.5 ml of a modified
Nonidet P-40 (NP-40) lysis buffer (0.5% NP-40, 10 mM HEPES [pH 7.6], 10 mM
NaCl, 3 mM CaCl, 5 mM MgCl2, 1 mM dithiothreitol, 100 U of RNasin per ml)
for 1 min on ice. After high-speed centrifugation (2 min at 4°C), the cytoplasmic
supernatant was collected and the cytoplasmic RNA was either extracted by
using the Total RNA isolation reagent kit or applied to a sucrose gradient (10 to
50%, wt/vol). A step sucrose gradient was prepared by overlaying 0.75 ml of 50,
40, 30, 20, and 10% sucrose-containing buffer (10 mM HEPES [pH 7.6], 10 mM
NaCl, 3 mM CaCl, 5 mM MgCl2, 1 mM dithiothreitol, 50 U of RNasin per ml),
and a linear gradient was formed by diffusion at 4°C for 16 h. The cytoplasmic
fraction was split in half, one sample was adjusted to 40 mM EDTA, and both
samples were layered on a sucrose gradient with or without EDTA (40 mM),
respectively. The gradients were centrifuged at 55,000 rpm for 75 min at 4°C in
a Beckman SW60Ti rotor. Ten fractions (0.4 ml) were collected by bottom
puncture of the tube, and the A260 of the fractions was measured. The RNA was
purified with the Total RNA isolation reagent kit and finally resuspended in 15
ml of RNase-free water.
RT-PCR and DNA-PCR analysis. A detailed description of the RT assay was
described recently (20). Briefly, purified total RNA (1 mg), mRNA (200 ng), or
gradient-fractionated RNA (5 ml per fraction sample) was reverse transcribed at
42°C in the presence of oligo(dT) primers, deoxynucleoside triphosphates, and
SuperScript-II enzyme as specified by the manufacturer (GibcoBRL, Melbourne,
Australia) in a 20-ml assay mixture. For RT-negative controls, the SuperScript-II
enzyme was omitted. Strand-specific RT reactions were performed under high-
stringency conditions at 56°C with 2 pmol of a sequence-specific primer and
SuperScript-II enzyme.
PCR amplifications (20 ml) were performed in PCR buffer containing 0.5 mM
each primer, 1 to 2 ml of first-strand cDNA sample or 10 to 50 ng of DNA, 200
mM each deoxynucleoside triphosphate, and 1 U of AmpliTaq DNA polymerase
(Perkin-Elmer). The ice-chilled samples were transfered to a 9600 GeneAmp
PCR instrument system (Perkin-Elmer), preheated at 85°C, and subjected to an
initial denaturation at 94°C for 1 min. This was followed by 30 to 35 cycles of
denaturation at 94°C for 20 s, primer annealing at 56 to 58°C for 30 s, and primer
extension at 72°C for 30 s and then a final extension at 72°C for 5 min. The
amplified products were separated by electrophoresis on 2.5 to 3% agarose gels
containing ethidium bromide in TAE buffer (40 mM Tris acetate, 1 mM EDTA
[pH 8.0]). The gel was photographed under UV light with Polaroid T-55 film, and
the relative amount of each DNA band was quantified using a Computing
Densitometer 300B system (Molecular Dynamics, Sunnyvale, Calif.).
Primers. The following oligonucleotide primers were used for amplification of
EBNA-3, EBNA-4, EBNA-6 (Fig. 1), and LMP-1 (their positions within the
B95.8 sequence [3] are given in parentheses): E3-intron-F, 59-CTAAGAACA
CTTCTTCAAGC (92547); E3-intron-R, 59-CTCGGTATTTGAAATCTGG
(92726); E3-intron-R2, 59-GATCCGAAAAACTGGTCTA (92707); E3-intron/
internal-F, 59-GTGAGCATCCCTATGGC (92582); E3-intron/internal-R, 59-C
TGAAACCAACGGCAACA (92669); E3-YPL-F, 59-GACGAGACAGCTA
CCAG (93624); E3-YPL-R, 59-GAGATACAGGGGGCAAG (93780); E4-
intron-F, 59-GGGATCTGAGCCTATTTCAC (95457); E4-intron-R, 59-TTC
CAACGCCTCTGCTTAAC (95933); E6-intron-F, 59-GACATCACACCATAT
ACCGC (98674); E6-intron-R, 59-TGTTAGAAGCCAATGTCGCC (98966);
LMP1-intron-F, 59-GATGAGGTCTAGGAAGAAGG (168884); and LMP1-in-
tron-R, 59-TCGCTCTCTGGAATTTGCAC (169113). The cDNA fragments
of b2-microglobulin (b2M, 131 bp), b-actin (410 bp), or EBNA-1 (240 bp)
were amplified with primers b2M59 (59-CCCCCACTGAAAAAGATGAG)
and b2M39 (59-TCACTCAATCCAAATGCGGC), p59Ac and p39Ac (41), or
E1-4-F (TTACAACCTAAGGCGAGGAA) and E1-6-R (ACAGTCACCCTG
ATATTGCA), respectively.
Northern blot analysis. Radiolabelled DNA probes were generated by PCR
amplification with the genomic EBNA-3 sequence and either primers E3-intron/
internal-F and E3-intron/internal-R (intron) or E3-YPL-F and E3-YPL-R (exon
2) (Fig. 1). A radiolabelled probe of b-actin was generated from oligo(dT)
reverse-transcribed cDNA of DG75 cells by using the b-actin-specific primers
p59Ac and p39Ac. The PCRs (100-ml mixtures) were performed for 30 cycles as
described above, except that 50 mCi of each [a-32P]dATP and [a-32P]dCTP
(3,000 Ci/mmol; DuPont) were added and 200 mM dGTP and dTTP and 6.3 mM
dATP and dCTP were used. The same PCR conditions were used to generate
radiolabelled single-stranded antisense EBNA-3 probes, except that the 59 prim-
er was used at a 50-fold-lower concentration (25).
mRNA (4 mg) was electrophoresed on a 1% agarose–formaldehyde gel in
MOPS/EDTA buffer (20 mM MOPS [3-(N-morpholino)propanesulfonic acid], 5
mM sodium acetate, 1 mM EDTA [pH 7.0]) at 55 V (constant voltage). After
electrophoresis, the RNA was transfered to a Hybond-N membrane (Amersham)
by capillary blotting and fixed onto the membrane by heating at 80°C for 2 h
under vacuum. The membranes were incubated for 1 h in hybridization buffer
(50% formamide, 53 SSPE [13 SSPE is 0.18 M NaCl, 10 mM NaH2PO4, and
1 mM EDTA, pH 7.7], 53 Denhardt’s solution, 0.5% sodium dodecyl sulfate
[SDS], 20 mg of salmon sperm DNA per ml), and radiolabelled probe was added
and hybridized at 42°C overnight. The filter was washed twice in 23 SSPE–0.1%
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SDS at room temperature for 10 min and once in 13 SSPE–0.1% SDS at 42°C
for 15 min and finally subjected to a high-stringency wash in 0.13 SSPE–0.1%
SDS at 42°C for 10 min. The blot was exposed to a Kodak Storage Phosphor
Screen at room temperature for 3 to 4 days for the EBNA-3 probes and for 1 day
for the b-actin probe, and the signals were analyzed on a PhosphorImager 400B
system (Molecular Dynamics). The filter was stripped by being washed three
times in boiling 0.1% SDS for 30 min each prior to reprobing.
S1 nuclease protection assay. To generate the S1 probe, the HindIII-BamHI
fragment of EBNA-3 (positions 91821 to 92705 [3] containing exon 1, the intron,
and the start of exon 2 [see Fig. 6A]) was cloned into pBluescriptKS with the
same enzyme sites and then linearized with BglII (which cut in exon 1). A
radiolabelled single-stranded DNA which was complementary to the EBNA-3
coding strand was generated by PCR in an 80-ml reaction mixture containing
PCR buffer, 200 ng of plasmid DNA, 312 nM M13 forward primer (which bound
to the plasmid backbone), 62.5 mM each dATP, dGTP, and dTTP, 1.25 mM
dCTP, 10 ml of [a-32P]dCTP (10 mCi/ml; 3,000 Ci/mmol [DuPont]), and 2.5 U of
Taq polymerase with 30 cycles of denaturation at 95°C for 60 s, primer annealing
at 52°C for 60 s, and primer extension at 72°C for 90 s. The PCR products were
ethanol precipitated, and the single-stranded S1 probe was purified on a 10%
polyacrylamide–8 M urea gel. The sequence composition of this 265-nucleotide
large probe is depicted in Fig. 5.
The S1 nuclease protection assay was performed with the S1 assay kit (Am-
bion, Austin, Tex.) as recommended by the manufacturer. Briefly, the radiola-
belled S1 probe was hybridized with mRNA or total RNA of cells expressing
EBNA-3. For controls, unrelated RNA from yeast or in vitro-transcribed RNA
from genomic or cDNA forms of EBNA-3 (both of which were cloned into
pBluescript and induced with the T3 promoter) were used. The single-stranded,
unprotected molecules were digested with S1 nuclease, and the remaining prod-
ucts were separated on a denaturing 10% polyacrylamide gel. The dried gels
were exposed to X-ray film overnight.
Immunoblot analysis. Cells were washed in PBS and lysed by being placed in
sample buffer (2% SDS, 5% a-monothioglycerol, 10% glycerol, 60 mM Tris-HCl
[pH 6.8], 0.001% bromophenol blue) with sonication and then boiled for 5 min.
Samples were subjected to SDS-polyacrylamide gel electrophoresis and electro-
transferred onto nitrocellulose filters (Amersham) with a minigel system (Bio-
Rad). The filters were stained with Ponceau S (Sigma) to confirm the presence
of even amounts of protein and were then preincubated for 1.5 h in Blotto buffer
(PBS, 0.1% Tween 20, 5% skim milk, 1% bovine serum albumin). For detection
of the EBNA-3 and EBNA-1 proteins, the filters were incubated with the EBV-
positive human serum MCr (diluted 1:50 in Blotto) for 1 h at room temperature.
For detection of the FLAG epitope EBNA-3, the commercial mouse anti-FLAG
M2 antibody (Kodak) was used. The filters were washed four times for 10 min
each in PBS–0.1% Tween 20 and incubated for 1 h with either horseradish
peroxidase-conjugated sheep anti-human immunoglobulin G (Amersham) or
horseradish peroxidase-conjugated sheep anti-mouse immunoglobulin G (Sile-
nus) at a 1:1000 dilution. The filters were washed as outlined above, and the
reactions were visualized by using the enhanced chemiluminescence Western
blotting detection system (Amersham). The relative amount of each protein
band was quantified with a Computing Densitometer 300B system (Molecular
Dynamics).
RESULTS
Intronic sequences are maintained in mRNA for EBNA-3,
EBNA-4, and EBNA-6. Vectors containing the genomic se-
quences of EBNA-3, EBNA-4, and EBNA-6 were stably trans-
fected into DG75 cells. The expression vector (EBO-pLLP)
contained the EBV-encoded EBNA1/oriP replicon enabling
episomal replication of the plasmid and an SV40 transcription-
al cassette driving recombinant gene expression. Cell clones
and bulk cultures of transfected cells containing the complete
gene family of EBNA 3 were designated EE346, whereas EE3,
EE4, and EE6 cells expressed the EBNA-3, EBNA-4, and
EBNA-6 proteins, respectively. Control cells (E) were trans-
fected with the expression vector only.
Total RNA and mRNA was prepared from transfected cells
and subjected to DNase I treatment, which we have previously
shown to be essential for the RT-PCR amplification of epi-
some-based genes (20). By using oligo(dT) primers, the
polyadenylated RNA was reverse transcribed and the result-
ing first-strand cDNA was PCR amplified with primer pairs
flanking the introns of EBNA-3, EBNA-4, and EBNA-6 (Fig.
1). Two cDNA species were obtained and were similar in size
to the spliced and unspliced control PCR products amplified
from DNA sequences of the genomic or cDNA versions of the
EBNA genes (Fig. 2A to C). Sequencing of these RT-PCR
products confirmed that they were indeed derived from spliced
and unspliced cDNA. The absence of any PCR products in the
RT-negative controls (Fig. 2, lanes 2) ruled out any detectable
contamination by genomic viral sequences. Several repetitions
of the experiment with transfected bulk cultures or cell clones
gave the same results and suggested that a significant propor-
tion of the EBNA-3, EBNA-4, and EBNA-6 mRNA transcripts
retained intron sequences.
The possibility that the RT-PCR products resulted from
RNA transcripts, expressed from the negative DNA strand,
was addressed by generating strand-specific cDNA. Strand-
specific RT reactions for the EBNA-3 intron were performed
under high-stringency conditions with either primer E3-in-
tron-F or E3-intron-R (Fig. 1), with total RNA or mRNA
prepared from EE3 and EE346 transfectants. The first-strand
cDNA samples were then PCR amplified with the same prim-
ers. PCR amplification of cDNA generated by the 39 primer
(E3-intron-R) resulted in the production of both spliced and
unspliced products, again with a predominance of the un-
spliced form (Fig. 2D, lanes 39). No products were detected
FIG. 1. Schematic diagram of EBV genes. The genomic organization of the
EBV genome and the two promoters driving EBNA gene expression is depicted.
The diagram is not drawn to scale. The gene structure of the EBNA 3 family is
illustrated, and the names and positions of primers are indicated. Introns and
exons are indicated in black and grey, respectively.
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when the 59 primer (E3-intron-F)-generated cDNA sample
was PCR amplified (Fig. 2D, lanes 59). These results demon-
strated that the unspliced EBNA-3 transcript did not originate
from an antisense RNA transcript and confirmed that the
results were not due to contamination with genomic EBNA-3
sequences.
Intron retention is specific for the EBNA 3 family genes. To
determine whether intron retention also occurred in EBV-
infected cell lines, RT-PCR was performed on total RNA and
mRNA isolated from a number of different LCLs (QIMR-
ISM, QIMR-KT, QIMR-NB, QIMR-PGP, QIMR-SB, and
B95.8) as well as the BL-cell line MutuIII-c95. The results
show that the vast majority of EBNA-3, EBNA-4, and EBNA-6
mRNA were unspliced in each of the EBV-positive cell lines
(Fig. 3A to C). The absence of any PCR-generated product in
the RT-negative controls (Fig. 3, lanes 2) confirmed that there
was no genomic DNA contamination.
To determine whether retention of intron sequences within
mRNA transcripts was restricted to the EBNA 3 family genes,
processing of transcripts from the latent viral LMP-1 gene
(which contains two small introns with nonconsensus splice
acceptor and donor sequences) was also analyzed by RT-PCR.
Primers LMP1-intron-F and LMP1-intron-R, which flanked
the second intron of LMP-1, were used to PCR amplify the
first-strand cDNAs generated from total RNA and mRNA
from different EBV-positive cell lines. As shown in Fig. 3D, the
spliced LMP-1 cDNA was the dominant form in both LCLs
and the BL-cell clones. These results indicate that intron re-
tention is specific for the genes of the EBNA-3 family.
Northern blot and S1 nuclease protection assays confirm
that EBNA-3 mRNA contains intronic sequences. To verify the
RT-PCR data, Northern blot and S1 nuclease protection as-
says were used to analyze the processing of the EBNA-3 RNA.
mRNA preparations from EE3 and vector control transfec-
tants, as well as from EBV-infected cells, were analyzed by
Northern blotting. The b-actin control demonstrated the in-
tegrity of the RNA and showed that similar amounts of the
RNA were present in each sample (Fig. 4, b-actin). A radio-
labelled EBNA-3 intron probe was generated by PCR ampli-
fication with primers E3-intron/internal-F and E3-intron/inter-
nal-R, which were specific for the intron sequence only. The
intron probe hybridized with a '4.7-kb mRNA (calculated by
comparison to the rRNAs) present in both LCLs and in EE3
cells but not in the vector control transfectants (Fig. 4, intron).
Hybridization with a higher-molecular-weight mRNA also oc-
curred in the sample derived from the LCLs (Fig. 4, intron,
lane 3). The use of a radiolabelled, single-stranded antisense
intron probe, generated by asymmetric PCR, and mRNA pre-
pared from three different LCLs gave the same results (data
not shown). The size of the intron-containing EBNA-3 mRNA
correlated well with previously published data showing that
EBNA-3 is encoded by a 4.5- to 5-kb mRNA (15, 34).
To determine the percentage of intron-containing EBNA-3
mRNA compared to fully spliced EBNA-3 mRNA, the filter
was deprobed and rehybridized with a radiolabelled probe
specific for the second exon of EBNA-3. This probe was gen-
erated by PCR amplification with primers E3-YPL-F and E3-
YPL-R (Fig. 1). The exon probe, which detects both unspliced
and spliced transcripts, resulted in the same hybridization pat-
tern and similar signal strength with respect to the intron probe
(Fig. 4, exon). The results indicate that the majority of the
EBNA-3 4.7-kb mRNA (as detected by the exon probe) con-
tained intron sequence (as detected by the intron probe). The
additional larger mRNA species, present in LCLs, to which the
intron and exon probes of EBNA-3 hybridized was likely to
consist of partially processed primary transcripts. When total
RNA of EE3 cells or LCLs was used as a target, no hybridiza-
tion signals could be detected with either the intron or exon
probes (data not shown), consistent with the low abundance of
EBNA-3 mRNA (18).
An S1 nuclease protection assay was performed to quantify
the ratio of unspliced to spliced RNA within the same sample.
A radiolabelled single-stranded antisense DNA probe which
covered the EBNA-3 intron and its flanking exon regions was
prepared. The probe also carried a random sequence of 98
nucleotides at its 59 tail. The expected digestion patterns of the
probes are illustrated in Fig. 5. For controls (Fig. 5, lanes 3 and
4), RNA was transcribed in vitro from the genomic or cDNA
form of EBNA-3 and the purified RNA and the probe were
subjected to the S1 nuclease assay. The intron-containing con-
trol RNA protected the EBNA-3 sequence within the probe
(167 n) but not its nonhomologous tail. The in vitro-tran-
scribed RNA of the EBNA-3 cDNA gave rise to the expected
fragments (40 n and 39 n). Surprisingly, a higher-molecular-
weight fragment, which may have been the result of stable
intermediate structures within the intronic sequence of the
EBNA-3 RNA, was also present. However, the control reac-
tion with nonhomologous yeast RNA in the presence or ab-
sence of S1 nuclease gave the expected results, indicating op-
timal S1 treatment conditions (Fig. 5, lanes 5 and 6). To
measure the degree of EBNA-3 intron retention in EBV-in-
fected or -transfected EE346 cells, the mRNA of the LCL
QIMR-MP or total RNA of EE346 cells was subjected to the
S1 nuclease assay. The protected unspliced probe fragment
was prominent, in contrast to the bands representing the
spliced EBNA-3 RNA (Fig. 5, lanes 1 and 2), indicating that
very little spliced RNA was present. Treatment of the RNA
with DNase I prior to the S1 nuclease assay did not abolish the
presence of the unspliced probe fragment. In contrast, pre-
treatment of the RNA with RNase A resulted in the complete
FIG. 2. Intron detection by RT-PCR from stably transfected cell lines. (A
and C) mRNA (lanes 1 and 3) and total RNA (lanes 2 and 4) were prepared from
DG75 cells expressing the complete family of EBNA 3 genes (EE346) or the
individual EBNA-3 (EE3) and EBNA-4 (EE4) genes (A and C). (B) Total RNA
of EE6 and EE346 cells was prepared. The RNA was reverse transcribed with
oligo(dT) primer, and the RT was omitted in an RT-negative control for the
EE346 RNA (2). The intron regions of EBNA-4 (A), EBNA-6 (B) and EBNA-3
(C) were PCR amplified from the first-strand cDNAs or from plasmid DNA
containing the genomic (U) or cDNA (S) sequence of the EBNA-4, EBNA-6, or
EBNA-3 genes. (D) mRNA from EE3 and total RNA from EE346 cells were
prepared. Strand-specific RNA was reverse transcribed with either sense primer
E3-intron-F (59) or antisense primer E3-intron-R (39), and the first-strand cD-
NAs were PCR amplified with both primers. All of the PCR products were
separated on a 2.5% agarose gel and visualized by ethidium bromide staining.
The positions and lengths (in base pairs) of the unspliced and spliced products
are indicated.
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digestion of the unprotected probe (data not shown). This data
confirmed the RT-PCR and Northern blot results, demonstrat-
ing that the vast majority of the EBNA-3 mRNA contained
intronic sequence.
Analysis of elements possibly involved in EBNA-3 intron
retention. Proteins expressed by alternatively spliced genes
(e.g., sxl of Drosophila) can autoregulate their own splicing
(36). To address whether the EBNA-3 protein itself may have
been involved in preventing the splicing of its own transcript,
a frameshift was introduced into the genomic EBNA-3 se-
quence (EBO-E3M; Fig. 6A). This mutated EBNA-3 gene was
stably expressed in DG75 cells. The frameshift, introduced into
the first exon of EBNA-3, allowed transcription of mRNA but
prevented translation of the EBNA-3 protein. Sequencing of
the mutated EBNA-3 gene verified the frameshift, and immu-
noblot analysis of the transfectants confirmed that the EBNA-3
protein was not expressed (data not shown). RT-PCR analysis
of mRNA preparations of EBO-E3M cell transfectants showed
that a high proportion of the mutated EBNA-3 mRNA still
contained the intron (Fig. 6B, lane EBO-E3M). This result was
confirmed by Northern blot analysis (data not shown) and
indicated that expression of the EBNA-3 protein was not nec-
essary for retention of intronic sequence in the EBNA-3
mRNA.
To determine whether a region of the EBNA-3 mRNA con-
tained elements involved in intron retention, a series of dele-
tion mutants were prepared, cloned into an expression vector
(EBO-pLPP), and stably expressed in DG75 cells (Fig. 6A).
The mRNA preparations from these transfectants were ana-
lyzed by RT-PCR. Deletion of the 39 untranslated region and
most of the second exon of the EBNA-3 mRNA alleviated
intron retention and resulted in predominantly spliced forms
of the EBNA-3 mRNA (EBO-E3BamHI; Fig. 6B). This sug-
gested that the mRNA downstream of the BamHI site may
have contained an element involved in intron retention. Con-
sequently, overlapping regions of the second exon were cloned
behind the BamHI site to try to identify this element (EBO-
E3HpaI, EBO-E3BseRI, EBO-E3EcoNI, and EBO-E3StuI;
Fig. 6A). Addition of any sequence 39 of the BamHI site re-
sulted in retention of the intron (Fig. 6B). One region in com-
mon in all of these constructs was the EBV-encoded EBNA-3
polyadenylation signal. To address the possible involvement of
this element, two constructs were created, one containing the
natural poly(A) signal (EBO-E3AATAAA) and the other con-
taining a mutated poly(A) signal (EBO-E3TTTAA) (Fig. 6A).
RT-PCR was again used to determine the degree of splicing of
the mRNA expressed by these constructs; however, both re-
sulted in intron retention (Fig. 6B). Finally, the 39 untranslated
region of EBNA-3 was completely removed, but again RT-
PCR showed the presence of intronic sequences (EBO-E3KpnI;
Fig. 6). Although Fig. 6B shows a slight decrease in intron re-
tention in the constructs of EBO-E3TTTAA and EBO-E3StuI,
the results presented at the right-hand side of Fig. 6A were a
summary of at least three different experiments showing that
the only construct consistently spliced was EBO-E3BamHI.
These results suggested that there was no element, within the
EBNA-3 mRNA, that was directly involved in intron retention
but, rather, that the spatial conformation of the RNA seemed
to be involved in the incomplete splicing of EBNA-3.
The transcriptional cassette of the expression vector used
contained the SV40 late polyadenylation signal, which was
located behind the EBV-encoded EBNA-3 poly(A) signal.
Since alternative poly(A) site selection can affect splicing (11),
we determined whether a preferential use of the EBV or SV40
poly(A) sites might be linked to intron retention. The trun-
cated forms of EBNA-3 mRNA, which either were predomi-
nantly spliced (EBO-E3BamHI) or retained the intronic se-
quence (EBO-E3StuI, EBO-E3TTTAAA), were amplified by
RT-PCR and sequenced to determine the poly(A) signal used
(data not shown). If both the EBV- and the SV40-encoded
polyadenylation signals were present together in the construct
(EBO-E3StuI), the unspliced as well as the spliced mRNA of
EBNA-3 utilized the EBV EBNA-3 poly(A) signal. Where the
EBV poly(A) signal was either absent (EBO-E3BamHI) or
mutated (EBO-E3TTTAAA), both spliced and unspliced
EBNA-3 mRNA contained the SV40 poly(A) signal, indicating
FIG. 3. RT-PCR detection of introns from EBV-infected cell lines. Total
RNA of MutuIII-c95 (lane 1), QIMR-ISM (lane 2), and QIMR-KT (lane 4) and
mRNA from QIMR-KT cells (lane 3) were reverse transcribed with an oligo(dT)
primer. The RT was omitted in a control for the QIMR-KT mRNA (2). The in-
tron regions of EBNA-3 (A), EBNA-4 (B), EBNA-6 (C), and LMP-1 (D) were
PCR amplified from the first-strand cDNAs or from genomic DNA of QIMR-KT
cells (1). The PCR products were separated on a 2.5% agarose gel and visual-
ized by ethidium bromide staining. The positions and lengths (in base pairs) of
the unspliced and spliced products are indicated.
FIG. 4. EBNA-3 intron detection by Northern blotting. mRNA was prepared
from transfected DG75 control cells (lane 1), EE3 cells (lane 2), or EBV-positive
QIMR-ISM cells (lane 3). The mRNA was electrophoresed on formaldehyde
gels, transferred to nitrocellulose, and hybridized with radiolabelled probes from
the EBNA-3 intron (intron), the second EBNA-3 exon (exon), or b-actin. The
positions of rRNA are indicated. Hybridization to EBNA-3 RNA is indicated by
arrowheads. Note that lanes 1 and 2 were derived from one autoradiograph and
lane 3 was derived from another.
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that there was no link between EBNA-3 intron retention and
the polyadenylation signal used.
The potential involvement of either the SV40 promoter (driv-
ing EBNA-3 transcription) or EBNA-1 (necessary for episomal
replication) in EBNA-3 intron retention was also analyzed
(Fig. 6A). The EBNA-3 gene was cloned between the RSV
promoter and the SV40 poly(A) site of the episomal expression
vector pREP4, creating expression vector REP-E3 (Fig. 6A).
This plasmid was either transiently or stably transfected into
DG75 cells, and immunoblot analysis of the cell extracts con-
firmed expression of the EBNA-3 protein (data not shown).
RT-PCR analysis of RNA prepared from the transfected cells
showed a predominance of EBNA-3 mRNA containing in-
tronic sequence (Fig. 6B, REP-E3). Finally, an EBNA-3 ex-
pression vector, which was based on REP-E3 but deleted in
EBNA-1, was constructed (Fig. 6A, REP/DE1-E3) and tran-
siently transfected into DG75 cells. Again, RT-PCR analysis
showed a predominance of intron-containing EBNA-3 mRNA
in the RNA from these cells (Fig. 6B, REP/DE1-E3), indicat-
ing that EBNA-1 was not involved in maintaining intronic se-
quence in the EBNA-3 mRNA.
Unspliced mRNA of the EBNA 3 family genes is transported
into the cytoplasm and associates with polysomes. Retention
of the introns within the EBNA 3 family mRNAs could regu-
late protein expression by preventing the transport of mRNA
into the cytoplasm. To address this, an EBV-positive LCL
(QIMR-SB) was separated into nuclear and cytoplasmic frac-
tions by using an NP-40 based lysis buffer. The cytoplasmic
RNA fraction was extracted and analyzed by RT-PCR with
oligo(dT) and primers flanking the intron of each of the genes
of the EBNA 3 family (Fig. 1). For controls, a 131-bp cDNA
fragment of the cellular b2-microglobulin gene was also ampli-
fied. As demonstrated in Fig. 7A, the EBNA-3, EBNA-4, and
EBNA-6 mRNAs present in the cytoplasmic fraction were pre-
dominantly unspliced (only EBNA-3 showed some detectable
spliced forms). This data indicated that the EBNA 3 family
mRNAs were transported into the cytoplasm, even though they
still contained introns, and raised the question whether these
mRNAs were free in the cytoplasm or associated with poly-
somes.
Therefore, polysomes were prepared by sucrose gradient
centrifugation of cytoplasmic extracts from the LCL QIMR-
SB. These were analyzed by RT-PCR to determine if the
FIG. 5. EBNA-3 intron detection by S1 nuclease protection assay. (Top)
Schematic diagram of the EBNA-3 gene with the restriction sites used for gen-
erating the probe and the nucleotide length (n) of the probe and its protected
fragments. First and second exons are shaded in grey, the intron is black, and the
nonhomologous 59 tail of the probe is cross-hatched. (Bottom) mRNA of QIMR-
MP cells (lane 1) and total RNA of EE346 cells (lane 2) were prepared. For
controls, either the cDNA (lane 3) or the genomic (lane 4) form of EBNA-3
RNA was transcribed in vitro or total RNA of yeast was used (lanes 5 and 6). The
RNA was hybridized with a radiolabelled antisense EBNA-3 probe carrying a
nonhomologous 59 tail, and the samples were treated with S1 nuclease (lanes 1
to 5) or left untreated (lane 6). The products were separated on a 10% dena-
turing sequencing gel and visualized by autoradiography. The positions of the
probe fragments and the xylene blue marker (55 n) are indicated.
FIG. 6. EBNA-3 intron retention in deletion constructs. (A) Schematic dia-
gram of EBNA-3 mutants showing the nucleotide insertion GATC (arrow) and
restriction sites used for cloning. The expression vector used is represented in the
initials of the constructs, EBO (EBO-pLPP) or REP (pREP4). REP/E1-E3 is
deleted in EBNA-1. Translation and polyadenylation signals, as well as the non-
translated regions (white), the exons (grey), and the intron (black) of EBNA-3,
are illustrated. The level of intron retention (summarized from at least three
different experiment) is given on the right. (B) RT-PCR with EBNA-3 intron-
flanking primers (E3-intron-F and E3-intron-R2) and mRNA from stable trans-
fectants expressing EBNA-3 deletion constructs. Transient transfectants of the
REP-E3 and REP/DE1-E3 plasmid transfectants were analyzed. For RT-PCR
details, see the legend to Fig. 3.
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mRNAs of EBNA-3, EBNA-4, and EBNA-6 were associated
with the polysomes. An identical assay was performed in the
presence of EDTA, which would disrupt the polysome struc-
ture. The sedimentation profile of the EBNA 3 family mRNAs
(which were almost exclusively unspliced) correlated well with
that obtained from the cellular b2-microglobulin mRNA, with
a significant proportion of the message sedimenting along with
the polysomes (Fig. 7B, bottom fractions). Disruption of the
intact polysomes by addition of EDTA resulted in a significant
proportion of the EBNA-3, EBNA-4, and EBNA-6 unspliced
mRNA and b2-microglobulin spliced mRNA being displaced
toward the top of the gradient (Fig. 7B). The A260 of the
gradient fractions demonstrated that the presence of EDTA
resulted in the disruption of the polysomes (Fig. 7C). This data
demonstrated that the unspliced mRNAs of the EBNA 3 fam-
ily genes were indeed transported into the cytoplasm and that
a significant proportion of this mRNA was physically associ-
ated with polysomes.
No EBNA-3 splice variant proteins are expressed. The as-
sociation of intron-containing EBNA-3 mRNA with the poly-
somes suggested that different forms of EBNA-3 protein might
be expressed. Since the EBNA-3 intron contained stop codons
in all three reading frames and the two EBNA-3 exons are
translated in different reading frames, nonremoval of the in-
tron could result in different EBNA-3 isoforms (see Fig. 9). To
investigate this possibility, the 8-aa FLAG immunoepitope
was introduced into exon 1 and the FLAG-tagged genomic
EBNA-3 sequence was stably expressed in DG75 cells. How-
ever, besides the full-length epitope tagged EBNA-3 protein,
no other FLAG epitope-containing protein form could be de-
tected in immunoblots. In addition, no other protein forms
(besides the full-length EBNA-3 protein) could be detected in
immunoblots when an EBV-seropositive serum was used (Fig.
8A and data not shown). These results suggested that intron
retention in EBNA-3 mRNA did not lead to different isoforms
of EBNA-3.
Intron retention influences EBNA-3 protein expression. The
high levels of intron-containing EBNA-3 mRNA in the cyto-
plasm suggested that the unspliced mRNA might influence the
level of protein expression. This was addressed by comparing
the amount of EBNA-3 protein expressed from either the
genomic or the cDNA form of the EBNA-3 gene. Both forms
of the EBNA-3 gene were cloned into expression vector EBO-
pLPP and were transfected into DG75 cells. Transient cell
transfectants were harvested 30 to 48 h after electroporation,
and protein expression was analyzed by immunoblotting with a
human serum directed against the EBNA proteins (Fig. 8A).
Surprisingly, the level of EBNA-3 protein expression was
higher in cells containing the genomic form of the EBNA-3
gene. The parallel detection of the level of EBNA-1 protein
(derived from the expression vector) confirmed that similar
levels of plasmid were present in the cells. Trypan blue cell
staining demonstrated that the viability of each of the trans-
fectants was similar. Protein extracts of the parental line DG75
and a vector-only transfected cell line were used as controls
(Fig. 8A). The differences in EBNA-3 protein expression were
FIG. 7. RT-PCR of fractionated cytoplasmic RNA. (A) RNA was prepared
from the cytoplasm of the LCL QIMR-SB and reversed transcribed with an
oligo(dT) primer (1). As a control, RT was omitted (2). The spliced and
unspliced cDNA fragments of the viral EBNA-3, EBNA-4, and EBNA-6 genes
and the spliced 131-bp cDNA fragment of the cellular b2-microglobulin gene
(b2-M) were amplified by PCR with intron-flanking primers. As a control, PCR
amplification of the genomic B95.8 virus DNA (DNA) was used. The positions
of unspliced and spliced PCR products are indicated. (B) The cytoplasmic RNA
was fractionated on a 10 to 50% sucrose gradient in the absence (left) or
presence (right) of EDTA. Ten fractions were collected (fraction 1 represents
the bottom of the gradient, and fraction 10 represents the top), and RNA present
in each of these fractions was analyzed by RT-PCR. (C) The A260 of each
gradient fraction was measured, and the fractions containing intact polysomes
are indicated. FIG. 8. The intron influences EBNA-3 protein expression. (A) DG75 cells
transfected with the cDNA (c) or the genomic (g) form of EBNA-3 were har-
vested after 30, 48, or 243 h (stable selection). DG75, parental cell line; E-C3,
stably selected control vector-transfected DG75 cells. The cell extracts were
analyzed by immunoblotting with an EBV-positive human serum. The positions
of the EBNA proteins are indicated by arrowheads, and size markers (in kilo-
daltons) are shown on the left. (B) Histogram of the densitometrically deter-
mined immunoblot signals of EBNA-3 protein shown as a ratio of genomic to
cDNA expressed EBNA-3 protein. Times of cell harvesting, number of experi-
ments (n), and error bars are indicated. (C) Total RNA of cells transfected for
48 h with the cDNA (c) or genomic (g) form of EBNA-3 were reverse transcribed
with an oligo(dT) primer. The intron-flanking region (E3-intron) and the second
exon (E3-YPL) of EBNA-3 (for primers, refer to Fig. 1), as well as the coding
regions of EBNA-1 and b2-microglobulin (b2-M), were PCR amplified from the
first-strand cDNAs. The PCR products were separated on an agarose gel and
visualized by ethidium bromide staining.
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reproducible in seven independent transient transfections per-
formed with a range of 10 to 25 mg of each plasmid DNA.
Within 48 h posttransfection, four- to sixfold more EBNA-3
protein was present in cells containing the genomic construct
than in cells containing the cDNA construct (Fig. 8B). At
56 h postelectroporation, EBNA-3 protein expression, be-
tween these two constructs, was less pronounced. Following
stable selection of cell bulk cultures (243 h), the levels of
EBNA-3 protein expression were similar in cell transfectants
expressing either the genomic form or the cDNA form of
EBNA-3 (Fig. 8A and B). This data indicated that the presence
of the intron may enhance the initial levels of EBNA-3 protein
expression.
The increase in protein expression could be due to the
EBNA-3 intron acting as a transcriptional activator. To ad-
dress this possibility, the mRNA steady-state levels in cells
transiently expressing either the genomic or cDNA form of
EBNA-3 were analyzed by RT-PCR (Fig. 8C). Amplification
of the second exon of EBNA-3 demonstrated similar amounts
of EBNA-3 mRNA in transfectants containing either the ge-
nomic form or the cDNA form of EBNA-3. As expected, the
EBNA-3 intronic sequence was retained in the transfectants
containing the genomic construct but not in cells containing
the cDNA construct. The control RT-PCR amplification of
EBNA-1 indicated similar levels of expression plasmids in both
types of transfectants, while amplification of b2-microglobulin
demonstrated similar amounts of cellular RNA. This data in-
dicated that the presence of the EBNA-3 intron did not en-
hance transcriptional activity but, rather, suggested that the
unspliced EBNA-3 mRNA, present in the cytoplasm, increased
protein expression.
DISCUSSION
The data presented in this report indicates for the first time
that the bulk of polyadenylated transcripts of the viral EBNA-
3, EBNA-4, and EBNA-6 genes contain intronic sequences
which are transported into the cytoplasm and associate with
polysomes. Intron retention occurred in both transfected BL
cells and EBV-positive BL cells and LCLs, indicating that this
represents the normal processing of EBNA-3, EBNA-4, and
EBNA-6 mRNA. Studies of the EBNA-3 gene by using the S1
nuclease protection assay and Northern blot analyses con-
firmed that the vast majority of polyadenylated EBNA-3 tran-
scripts contain intron sequence. Since the size of these tran-
scripts is virtually identical to that of the fully spliced mRNA,
it is understandable that they have not been detected in pre-
vious studies in which probes specific for the coding region of
EBNA-3 were used (15, 34).
In mammalian cells, pre-mRNAs are usually processed in a
highly coordinated fashion involving formation of a cap at the
59 end, excision of introns, and polyadenylation of the 39 end.
A model for selection of splice sites (exon definition model) in
which exons and not introns are the basic units recognized by
the splicing machinery has been proposed (29). First exons are
defined by interactions between factors which recognize the 59
cap and the 59 splice donor site. Terminal exons are defined by
interactions between factors recognizing both the 39 splice
acceptor sites and polyadenylation sites (reviewed in reference
5). Our data demonstrate that intron retention occurs within
the EBNA 3 family transcripts derived from three different
promoters (EBV, SV40, and RSV), suggesting that it is inde-
pendent of promoter usage. Neither the full-length EBNA-3
gene nor the coordinate expression of all of the three EBNA 3
family genes was needed for intron retention, suggesting that
this feature is intrinsic to the structure of each of these genes.
Sequence analysis of the introns and their flanking regions
showed that they did not have perfect homology to the con-
sensus mammalian splice signals (Fig. 9). Suboptimal 59 donor
and 39 acceptor splice sites can reduce the efficiency of splicing,
leading to the retention of introns, as seen for the bovine
growth hormone (10). This premise is supported in the “exon
definition model,” which requires weak splicing signals for
differential splicing to occur (29). Recent data from polyoma-
virus late mRNA studies demonstrated that a suboptimal 59
splice site leads to accumulation of unspliced mRNA, which is
able to enter the cytoplasm (16). These authors suggested that
the process of splicing was not necessary for mRNA export
into the cytoplasm. Splicing of introns can be influenced by cis-
or trans-acting mechanisms. Exonic splicing enhancers most
commonly promote removal of the flanking upstream intron by
interacting with cellular splicing factors (17). Alternatively,
exon sequences which repress splicing have been described, par-
ticularly if the exons carry weak splice sites (9). The EBNA-3
deletion constructs indicated that an exonic splicing-inhibitory
element was probably not involved in intron retention in
EBNA-3 mRNA. Although loss of most of the second EBNA-3
exon resulted in predominantly spliced EBNA-3 mRNA, the
addition of any EBNA-3 RNA after the 39 acceptor site of the
EBNA-3 intron facilitated intron retention. One possible ex-
planation for this phenomenon is that the additional RNA may
be stabilizing some secondary structure within the mRNA, there-
by inhibiting splicing. Sequences within an intron can reduce
the efficiency of intron removal. In viruses like minute virus of
mice or RSV, intronic sequences inhibit the splicing of introns,
resulting in a significant portion of unspliced, polyadenylated
viral RNA in infected cells (2, 46). Secondary RNA structures
within the intron have been reported to control alternative
splice site selection for the generation of isoforms of the hu-
man growth hormone (12). It is of interest that analysis of min-
imal free energy release predicted an RNA stem-loop within
the EBNA-3 intron, suggesting that this structure might be in-
volved in intron retention.
The EBV genome and the vectors used to express the genes
of the EBNA 3 family always expressed EBNA-1, which is
necessary for the replication of the episome. EBNA-1 is also
known to bind RNA via RGG binding motifs located in the
N-terminal half of the protein (37), suggesting that EBNA-1
might be involved in the process of intron retention. However,
deletion of most of the EBNA-1 (resulting in the loss of RNA
binding [37]) in the EBNA-3 expression vector did not affect
the level of unspliced EBNA-3 mRNA. From studies of devel-
opmental genes of Drosophila (e.g., sxl, tra and dsx), it is known
that the proteins, expressed from mRNA in which intron re-
tention or exon skipping occurs, can regulate their own expres-
FIG. 9. Intron sequences of the EBNA 3 family genes. The aligned exon
(lowercase) and intron (capital) RNA sequences of EBNA-3, EBNA-4, and
EBNA-6 (B95.8 strain [3]) and their consensus sequence are presented. Dots and
dashes represent gaps; the asterisk indicates the potential branch point. The
mammalian splice donor and acceptor consensus sequences are given in boldface
type. Note that the first and second exons of EBNA-3 and EBNA-6 undergo a
frameshift after splicing.
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sion (reviewed in reference 36). However, data from the frame-
shifted EBNA-3 mutant (resulting in EBNA-3 mRNA but not
protein expression) showed that the EBNA-3 protein did not
influence the splicing of its own mRNA. This indicated that
EBNA-1 and EBNA-3 were not likely to be involved in intron
retention within EBNA-3 mRNA but, rather, that cellular fac-
tors were probably involved.
Although constitutive splicing of intronic sequences from
RNA is the dominant form of gene expression, intron reten-
tion, as a form of alternative splicing, has been observed to
occur in a number of different genes. Examples of intron re-
tention have been found in the transcripts encoding fibronec-
tin, platelet-derived growth factor A chain, and bovine growth
hormone and during the developmental control of Drosophila
genes. Viruses, such as influenza virus or RSV, produce pri-
mary transcripts used in both spliced and unspliced forms to
produce different functional proteins (36). Proteins expressed
from either the first or second exon of the EBNAs may have
functions distinct from the full-length gene products. How-
ever, the immunoblot analysis with FLAG-tagged or wild-
type EBNA-3 gave no evidence for the existence of different
protein isoforms of EBNA-3.
Retained introns can introduce stop codons in the open
reading frame or frameshifts, both of which can lead to pre-
mature termination of translation. Thus, intron retention can
regulate gene expression without changing transcriptional ac-
tivity. Premature termination of translation of a transcript is
almost as economical as regulating initiation of transcription,
since most of the expense in expressing a gene occurs at the
translational level (6). This is particularly true if the transcript
is very large and the first exon is small, as is the case for the
EBNA 3 family genes. Each of the introns within the EBNA 3
gene family contains stop codons in all three reading frames, as
well a frameshift is required for EBNA-3 and EBNA-6 protein
expression. Hence, the presence of the intron would effectively
disrupt the translation process. In this context, a recent paper
reports that an intron-containing mRNA was associated with
polysomes but was not translated unless the intron was re-
moved (7). This intron was both necessary and sufficient to
prevent complete translation of polysome-associated mRNA,
and this suggested a novel process by which translation of a
mRNA could be attenuated. In light of this, intron retention in
the EBNA 3 family mRNAs might serve a similar function in
the regulation of translation of these mRNAs. In contrast, it
was surprising that the transfection data indicated that reten-
tion of the EBNA-3 intron could enhance protein expression,
since up to sixfold more EBNA-3 protein was detected in
transiently transfected cells expressing the genomic form of
EBNA-3 than in those expressing the cDNA form. Interest-
ingly, when transient and stable transfectants were compared,
the level of genomic expressed EBNA-3 protein did not in-
crease during the hygromycin selection of stable EBNA-3 cell
transfectants. This could indicate that there is a maximal limit
on the level of EBNA-3 protein tolerable by the cell and this
level was already reached during transient transfection. Thus
subsequent increase in the level of EBNA-3 protein might be
prevented by regulatory factors within the cell. Alternatively,
cells overexpressing EBNA-3 may have been negatively se-
lected, as seen for EBV-encoded LMP-1, which is toxic when
overexpressed (14). In contrast, the initially low expression
levels of EBNA-3 protein steadily increased between 30 and
243 h posttransfection in cells containing the EBNA-3 cDNA.
Finally, the cDNA EBNA-3 stable cell transfectants expressed
similar amounts of protein to the cells containing the genomic
EBNA-3. Assuming a 10% transfection efficiency for the EBNA-
3 expression vectors (as judged by a green fluorescent protein
reporter plasmid), the initial minor fraction of cells containing
the EBNA-3 cDNA expanded during the process of stable hy-
gromycin selection, leading to an overall increase of EBNA-3
protein levels. Up to fivefold-higher levels of protein and RNA
expression from genomic intron-containing DNA, relative to
cDNA, have been reported previously for a Drosophila gene
(26). The authors claimed that the increased level of expres-
sion was due to higher levels of transcription mediated by an
intron enhancer. In contrast, our RT-PCR data measuring
the steady-state levels of the transiently expressed EBNA-3
mRNA indicated that the transcription rates for the genomic
and cDNA-derived EBNA-3 gene were similar. One possible
explanation is that the EBNA-3 intron did not influence the
transcription rate of the expression plasmid but, rather, af-
fected the stability, transport, or translation of the RNA. In-
creased levels of EBNA-3 mRNA might be transported to the
cytoplasm in the cells expressing the genomic EBNA-3 con-
struct compared to those in the intronless construct. However,
retaining the intron in the EBNA-3 mRNA seems to help
increase the overall expression efficiency, and the association
of unspliced EBNA-3 mRNA with the polysomes implies an
influence on protein translation.
It is intriguing that the introns of the EBNA-3 family genes
are strongly conserved between the A and B types of EBV,
which are otherwise characterized by pronounced differences
in the coding regions of these genes. This selective conversa-
tion strongly implies that the introns serve an important func-
tion. Despite the conservation of the introns between the two
types of EBV, the introns of EBNA-3, EBNA-4, and EBNA-6
do not have significant homology (Fig. 9). Except for the splic-
ing signals (donor and acceptor sites, branch point, and poly-
pyridine tract), the introns have no consensus sequence, sug-
gesting that the mechanism of intron retention in the EBNA-3,
EBNA-4, and EBNA-6 mRNAs would be different. This could
lead to individual regulation of the expression of each of
these genes. Indeed, as all three gene products seem to
directly compete with the cellular transcription factor RBP-
Jk/2N, which modulates viral and cellular gene expression (31,
42), one has to postulate that their protein expression must be
individually regulated. This could be achieved by cellular fac-
tors which interact with different elements in the introns and
regulate the levels of intron retention. Since the EBNA 3
family proteins are essential for transformation and survival of
EBV-infected B cells (35, 40), EBV must maintain adequate
control over their expression. All the EBNA RNAs are en-
coded from a large primary transcript initiated from the viral
Cp or Wp promoter. Hence, altering the rates of transcription
from these promoters would result in the regulation not of in-
dividual EBNA genes but of the whole set of genes. In con-
trast, intron retention might provide a means of individually
controlling the expression of each of the EBNA-3, EBNA-4,
and EBNA-6 proteins.
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